Search Result

Results for "

human CB1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) ANGPTL (1) Apoptosis (1) Autophagy (4) Cannabinoid Receptor (28) Cytochrome P450 (1) DAGL (1) EGFR (1) Endogenous Metabolite (2) Interleukin Related (1) Isotope-Labeled Compounds (1) mTOR (1) NF-κB (3) Orphan GPCR (1) P-glycoprotein (1) PI3K (1) Reference Standards (2) TNF Receptor (1) TRP Channel (1) VEGFR (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Inflammation/Immunology (12) Metabolic Disease (12) Neurological Disease (11)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0919

Yangonin 1 Publications Verification	Cannabinoid Receptor NF-κB Autophagy	Inflammation/Immunology
Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a K_i of 1.79 μM and 0.72 μM, respectively.

HY-10013

Taranabant 2 Publications Verification MK-0364	Cannabinoid Receptor	Metabolic Disease
Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding K_i of 0.13 nM for the human CB1R in vitro.

HY-10871

Otenabant 2 Publications Verification CP-945598	Cannabinoid Receptor	Metabolic Disease
Otenabant is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-112340

CB1 antagonist 4	Cannabinoid Receptor	Neurological Disease Metabolic Disease
CB1 antagonist 4 (compound 8) is a selective cannabinoid receptor 1 (CB1) inverse agonist with an IC₅₀ of 8.5 nM for human CB1. CB1 antagonist 4 shows selective for CB1 over CB2 receptors (IC₅₀ of 604.9 nM). CB1 antagonist 4 inhibits GTP binding to CB1-overexpressing cell membranes with an EC₅₀ of 18.5 nM .

HY-100488

Bay 59-3074	Cannabinoid Receptor	Cancer
Bay 59-3074 is a selective cannabinoid CB₁/CB₂ receptor partial agonist with K_i values of 48.3 and 45.5 nM at human *CB₁* and CB₂ receptors, respectively. Bay 59-3074 has analgesic properties .

HY-103325

JTE-907	Cannabinoid Receptor TRP Channel Interleukin Related ANGPTL VEGFR	Metabolic Disease Inflammation/Immunology
JTE-907 is a selective and orally active cannabinoid CB2 receptor inverse agonist and exerts anti-inflammatory effects. JTE-907 upregulates IL-6, MCP-1, IL-1β, VEGF, ANGPTL4, and TRPV1 in mature adipocytes. JTE-907 downregulates CB1, MCP-1, and IL-1β in preadipocytes. JTE-907 inhibits ear swelling in mice. JTE-907 reverses the protective effects of CB2 agonists and Anandamide (HY-10863) against cytokine-evoked colonic mucosal damage. JTE-907 can be used for the research of allergic dermatitis, obesity, and colitis .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_i*s of 857 nM and 598 nM for human* recombinant CB1 and CB2 receptors, respectively .**

HY-119104

AZD1940 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
AZD1940 is an orally active, high affinity *cannabinoid CB1/CB2* receptor agonist with pK_i values of 7.93 and 9.06 for human CB1R and CB2R**, respectively. AZD1940 shows a robust analgesia action .

HY-130311

2-Linoleoyl glycerol 2-Monolinolein; 2-Monolinoleoylglycerol	Cannabinoid Receptor	Neurological Disease
2-Linoleoyl glycerol (2-Monolinolein) is a partial CB1 receptor agonist with a pEC₅₀ of 4.781. 2-Linoleoyl glycerol activates the hCB1 receptor. 2-Linoleoyl glycerol does not induce an increase in intracellular free Ca ²⁺. 2-Linoleoyl glycerol can be used in the research of neurological disorders .

HY-177425

AM11542	Cannabinoid Receptor	Metabolic Disease
AM11542 is a cannabinoid receptor 1 (CB1) agonist with a human CB1 K_i of 0.11 nM. AM11542 stabilizes the active conformational state of the CB1 receptor. AM11542 can be used for the research of obesity .

HY-120851

O-7460	Cannabinoid Receptor DAGL	Metabolic Disease
O-7460 is a potent and selective DAGLα inhibitor, with an IC₅₀ of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels .

HY-122964

URB447	Cannabinoid Receptor	Metabolic Disease
URB447 is a peripherally restricted *CB₁* cannabinoid antagonist (IC₅₀: 313 nM and 41 nM for rat CB1 and human CB2 receptor respectively ). URB447 lowers food intake and body-weight gain in mice without entering the brain or antagonizing central CB₁-dependent responses. URB447 can be used for research of obesity .

HY-110003

Arachidonylcyclopropylamide 2 Publications Verification ACPA	Cannabinoid Receptor	Neurological Disease
Arachidonylcyclopropylamide (ACPA) is a potent and selective CB1 receptors agonist. Arachidonylcyclopropylamide inhibits forskolin-stimulated cAMP production in CHO cells transfected with human cannabinoid CB1 receptors (IC₅₀=2 nM) .

HY-N6932

Voacamine	Cannabinoid Receptor P-glycoprotein PI3K Akt mTOR Apoptosis Autophagy EGFR	Metabolic Disease Cancer
Voacamine is an indole alkaloid with cannabinoid 1 (CB1) antagonistic activity. Voacamine can inhibit nuclear translocation. Voacamine is effective in enhancing the effect of Doxorubicin (HY-15142A) as it interferes with the P-glycoprotein (P-gp) function. Voacamine promotes apoptosis-independent autophagic cell death in human osteosarcoma cells. Voacamine activates mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway to suppress breast cancer progression. Voacamine inhibits EGFR to exert oncogenic activity against colorectal cancer .

HY-159161

PSB-CB-27	Orphan GPCR	Inflammation/Immunology Cancer
PSB-CB-27 is a potent and selective GPR18 inhibitor with an IC₅₀ of 0.65 μM. PSB-CB-27 shows selectivity over Human GPR55, Human CB1 receptor, and Human CB2 receptor. PSB-CB-27 leads to a complete blockade of Δ9-Tetrahydrocannabinol (THC)-induced GPR18 activation. PSB-CB-27 can be used for inflammatory diseases and cancer immunotherapy research .

HY-10871A

Otenabant Hydrochloride CP 945598 Hydrochloride	Cannabinoid Receptor	Metabolic Disease
Otenabant Hydrochloride is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-152581

CB2R antagonist 3	Cannabinoid Receptor	Inflammation/Immunology
CB2R antagonist 3 is a selective antagonist of cannabinoid type 2 receptor (CB2R). CB2R antagonist 3 has high affinity for human CB2R and specific selectivity for CB1R. CB2R antagonist 3 can be combined with CB65 (HY-110047), the activator of CB2R. CB2R antagonist 3 effectively up-regulates the expression of anti-inflammatory cytokines and down-regulates the expression of pro-inflammatory cytokines .

HY-152576

CB2R agonist 1	Cannabinoid Receptor	Inflammation/Immunology
CB2R agonist 1 is a selective ligand of cannabinoid receptor subtype 2 (CB2R) with an EC₅₀ value of 0.56 µM. CB2R agonist 1 has high affinity and excellent selectivity for human CB2R and *CB1R* respectively. CB2R agonist 1 regulates the production of pro-inflammatory cytokines and anti-inflammatory cytokines and play an immunomodulatory role .

HY-172568

(±)5(6)-EET Ethanolamide	Cannabinoid Receptor Cytochrome P450	Neurological Disease Inflammation/Immunology
(±)5(6)-EET Ethanolamide is a metabolite of Anandamide (HY-10863) generated via oxidation by cytochrome P450 enzymes. (±)5(6)-EET Ethanolamide is also a selective cannabinoid receptor 2 (CB2) agonist. (±)5(6)-EET Ethanolamide has K_i values of 11.4 μM and 8.9 nM for human *CB1* and CB2, respectively . (±)5(6)-EET Ethanolamide can be used in research on immunomodulation and neuroinflammation .

HY-119744

BAY 38-7271	Cannabinoid Receptor	Neurological Disease
BAY 38-7271 is selective and highly potent and cannabinoid CB₁/CB₂ receptor agonist, with K_is of 1.85 nM and 5.96 nM for recombinant human CB₁ receptor and CB₂ receptor, respectively. BAY 38-7271 has strong neuroprotective properties .

HY-113885

MDA77	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
MDA77 is a CB2 inverse agonist with an EC₅₀ of 5.82 nM, showing selectivity for human CB2 and no activity on *CB1* .

HY-P1397A

RVD-Hpα TFA	Cannabinoid Receptor	Cardiovascular Disease
RVD-Hpα TFA is the N-terminally extended form of human hemopressin that acts as a selective CB1 receptor agonist. RVD-Hpα TFA increases intracellular Ca ²⁺ levels in cells expressing CB1 receptors in vitro. RVD-Hpα TFA also high affinity CB2 positive allosteric modulator (K_i=50 nM).

HY-134110

N-Methylarachidonamide	Endogenous Metabolite	Metabolic Disease
Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N-methyl amide is an analog of anandamide that binds to the human central cannabinoid (CB1) receptor with a Ki of 60 nM. It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.

HY-N15177

Δ9-THCB Δ9-Tetrahydrocannabutol	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
Δ9-THCB (Δ9-Tetrahydrocannabutol) has a high affinity for human *CB1* and CB2 receptors with the K_i values of 15 nM and 51 nM, respectively. Δ9-THCB (Δ9-Tetrahydrocannabutol) has analgesic and anti-inflammatory activities and plays partial agonistic effects on *CB1* receptor in mice .

HY-134055

Arachidonoyl-N,N-dimethyl amide Arachidonic acid-N,N-dimethyl amide	Cannabinoid Receptor	Metabolic Disease
Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N,N-dimethyl amide is an analog of anandamide that exhibits weak or no binding to the human central cannabinoid (CB1) receptor (Ki >1 μM). It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.

HY-N0919R

Yangonin (Standard)	Reference Standards Cannabinoid Receptor NF-κB Autophagy	Inflammation/Immunology
Yangonin (Standard) is the analytical standard of Yangonin. This product is intended for research and analytical applications. Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC50 and a Ki of 1.79 μM and 0.72 μM, respectively.

HY-W705168

Yangonin-d3	Isotope-Labeled Compounds Autophagy Cannabinoid Receptor NF-κB	Inflammation/Immunology
Yangonin-d₃ is the deuterium labeled Yangonin (HY-N0919). Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a Ki of 1.79 μM and 0.72 μM, respectively.

HY-124954

MN-25	Cannabinoid Receptor TNF Receptor	Neurological Disease Inflammation/Immunology
MN-25 (compound 4a) is an orally active indolpyridone that serves as a novel cannabinoid ligand. MN-25 has K_i of 245 nM and 11 nM for *CB1* and CB2. MN-25 has CB2 agonist activity and inhibits TNF-R release in human peripheral blood mononuclear cells in vitro with an IC₅₀ of 33 μM. MN-25 shows efficacy in a mouse acute inflammation model at oral doses up to 50 mg/kg ^>[1].

HY-10871R

Otenabant (Standard) CP-945598 (Standard)	Reference Standards Cannabinoid Receptor	Metabolic Disease
Otenabant (Standard) is the analytical standard of Otenabant (HY-10871). This product is intended for research and analytical applications. Otenabant is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-179436

9β,10β-epoxy Hexahydrocannabinol 9β,10β-EHHC; 9β,10β-epoxy HHC	Cannabinoid Receptor	Neurological Disease
9β,10β-epoxy Hexahydrocannabinol is a cannabinoid receptor 1 (CB1) and CB2 receptor ligand with a binding affinity of 224 nM for CB1 and 335 nM for CB2. 9β,10β-epoxy Hexahydrocannabinol reduces locomotor activity, induces catalepsy, lowers body temperature, and produces antinociceptive effects in mice. 9β,10β-epoxy Hexahydrocannabinol can be used for the study of nervous system diseases .

Cat. No.	Product Name	Target	Research Area

HY-P1397A

RVD-Hpα TFA	Cannabinoid Receptor	Cardiovascular Disease
RVD-Hpα TFA is the N-terminally extended form of human hemopressin that acts as a selective CB1 receptor agonist. RVD-Hpα TFA increases intracellular Ca ²⁺ levels in cells expressing CB1 receptors in vitro. RVD-Hpα TFA also high affinity CB2 positive allosteric modulator (K_i=50 nM).

Cat. No.	Product Name	Target	Research Area	Image

HY-P990590

GFB-024	Inhibitory Antibodies	Inflammation/Immunology
GFB-024 is a CHO-expressed humanized antibody that targets *CB1/CNR1. GFB-024 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GFB-024 can refer to Human* IgG1 kappa, Isotype Control (HY-P99001).

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0919

Yangonin 1 Publications Verification	other families Classification of Application Fields Other Phenylpropanoids Phenylpropanoids Plants Inflammation/Immunology Disease Research Fields Source Classification	Cannabinoid Receptor NF-κB Autophagy
Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a K_i of 1.79 μM and 0.72 μM, respectively.

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Cannabinoid Receptor Endogenous Metabolite
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_i*s of 857 nM and 598 nM for human* recombinant CB1 and CB2 receptors, respectively .**

HY-N6932

Voacamine	Alkaloids other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Indole Alkaloids Source Classification	Cannabinoid Receptor P-glycoprotein PI3K Akt mTOR Apoptosis Autophagy EGFR
Voacamine is an indole alkaloid with cannabinoid 1 (CB1) antagonistic activity. Voacamine can inhibit nuclear translocation. Voacamine is effective in enhancing the effect of Doxorubicin (HY-15142A) as it interferes with the P-glycoprotein (P-gp) function. Voacamine promotes apoptosis-independent autophagic cell death in human osteosarcoma cells. Voacamine activates mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway to suppress breast cancer progression. Voacamine inhibits EGFR to exert oncogenic activity against colorectal cancer .

HY-N15177

Δ9-THCB Δ9-Tetrahydrocannabutol	Monophenols Cannabis sativa L Phenols Plants Moraceae Source Classification	Cannabinoid Receptor
Δ9-THCB (Δ9-Tetrahydrocannabutol) has a high affinity for human *CB1* and CB2 receptors with the K_i values of 15 nM and 51 nM, respectively. Δ9-THCB (Δ9-Tetrahydrocannabutol) has analgesic and anti-inflammatory activities and plays partial agonistic effects on *CB1* receptor in mice .

HY-N0919R

Yangonin (Standard)	Structural Classification other families Other Phenylpropanoids Phenylpropanoids Plants Source Classification	Reference Standards Cannabinoid Receptor NF-κB Autophagy
Yangonin (Standard) is the analytical standard of Yangonin. This product is intended for research and analytical applications. Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC50 and a Ki of 1.79 μM and 0.72 μM, respectively.

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P700408

	*CNR1 Protein-VLP, Human* (HEK293, His)** cannabinoid receptor 1 (brain); CNR; cannabinoid receptor 1; CANN6; CB R; CB1; CB1A; CB1K5; central cannabinoid receptor; CB-R; CB1R;	Human	HEK293
	CNR1 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

HY-P704544

	*CNR1 Protein-VLP, Human* (T210A, HEK293)** cannabinoid receptor 1 (brain); CNR; cannabinoid receptor 1; CANN6; CB R; CB1; CB1A; CB1K5; central cannabinoid receptor; CB-R; CB1R;	Human	HEK293
	CNR1 Protein-VLP, Human (T210A, HEK293) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W705168

Yangonin-d3
Yangonin-d₃ is the deuterium labeled Yangonin (HY-N0919). Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a Ki of 1.79 μM and 0.72 μM, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

human CB1

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products